Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deanna Kamienski

Senior Deals Analyst, Biomedtracker

Deanna has been tracking deal-making activity in the biopharma and medtech industries since 2000. She is currently a Senior Deals Analyst for Biomedtracker and had previously contributed to the Strategic Transactions deals database. Deanna authors a Quarterly Statistics article and other monthly trend pieces for In Vivo. She holds a Bachelor of Science degree from the University of Vermont..

Latest From Deanna Kamienski

Deals In Depth: August 2020

Biogen and Denali entered into a potential $2.15bn alliance for Denali’s DNL151 for Parkinson’s disease and other neurodegenerative diseases. Siemens Healthineers announced plans to acquire Varian Medical for $16.4bn. Financing reached $7.9bn in biopharma, $501m in device, and $639m in diagnostics.

BioPharmaceutical Medical Device

Deals In Depth: July 2020

Daiichi Sankyo partnered its Phase I DS-1062 for non-small cell lung cancer and triple negative breast cancer with AstraZeneca in a deal that could be worth up to $6bn. Medtronic entered into an agreement to acquire Medicrea in an all-cash tender offer for total consideration of approximately $228m (including approximately $57M of net cash and liabilities). Financing reached $11.7bn in biopharma, $1.4bn in device, and $597m in diagnostics.

Deals Market Intelligence

Dealmaking Quarterly Statistics, Q2 2020

During Q2 biopharmas reached $5.9bn in merger and acquisition value and drew in $44bn in potential deal value from alliances. Device company M&A values reached $159m, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $1.4bn.

Deals BioPharmaceutical

Financing Quarterly Statistics, Q2 2020

During Q2 biopharmas brought in an aggregate $32.3bn in financings and device company fundraising totaled $9.5bn; while in vitro diagnostic firms and research tools players brought in $2bn across the period.

Deals Market Intelligence

Deals In Depth: June 2020

Genmab and AbbVie penned a broad oncology collaboration worth up to $3.9bn. Novo Nordisk entered into an agreement to acquire Corvidia Therapeutics for $725m up front in cash and up to $1.375bn in earn-outs.

Deals Market Intelligence

Deals In Depth: May 2020

Repare Therapeutics and Bristol Myers Squibb announced a multi-target discovery collaboration potentially worth over $3bn. Alexion Pharmaceuticals entered into a definitive agreement to acquire fellow public biotech Portola Pharmaceuticals $1.44bn. An increase in both follow-on public offerings and PIPE financings boosted biopharma financing significantly from last month.

Deals Market Intelligence
See All
UsernamePublicRestriction

Register